3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Stomach Neoplasms
16
Lung Neoplasms
9
Neoplasm Metastasis
5
Neoplasms
4
Adenocarcinoma
4
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Thymoma
2
Rectal Neoplasms
2
Non-small Cell Lung Cancer Metastatic
2
Malignant Solid Tumor
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Metastatic Small Intestinal Adenocarcinoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Interventions
tusamitamab ravtansine
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma Gastric
×
Ramucirumab
×
Clear all
NCT05071053
2025-08-22
CARMEN-GC01
Sanofi
Phase 2
Terminated
35 enrolled
14 charts